SCWorx（WORX）株式概要SCWorx Corp.は、その子会社とともに、米国の医療提供者向けに情報の修復、正規化、相互運用性に関するデータコンテンツとサービスを提供している。 詳細WORX ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績0/6財務の健全性4/6配当金0/6リスク分析意味のある時価総額がありません ( $395K )キャッシュランウェイが1年未満である 過去1年間で株主の希薄化は大幅に進んだ US市場と比較して、過去 3 か月間の株価の変動が非常に大きい+1 さらなるリスクすべてのリスクチェックを見るWORX Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$0.3747.9% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-7m5m2016201920222025202620282031Revenue US$1.5mEarnings US$169.2kAdvancedSet Fair ValueView all narrativesSCWorx Corp. 競合他社iTonic HoldingsSymbol: NasdaqCM:ITOCMarket cap: US$5.3mBiotricitySymbol: OTCPK:BTCYMarket cap: US$3.5mHealthcare TriangleSymbol: NasdaqCM:HCTIMarket cap: US$4.9miSpecimenSymbol: NasdaqCM:ISPCMarket cap: US$6.2m価格と性能株価の高値、安値、推移の概要SCWorx過去の株価現在の株価US$0.3752週高値US$12.0152週安値US$0.28ベータ1.631ヶ月の変化-63.00%3ヶ月変化-92.96%1年変化-93.87%3年間の変化-99.39%5年間の変化-99.89%IPOからの変化-99.90%最新ニュースお知らせ • Apr 15SCWorx Corp.(OTCPK:WORX) dropped from NASDAQ Composite IndexSCWorx Corp. has been dropped from the NASDAQ Composite Index .お知らせ • Apr 11SCWorx Corp. Faces Nasdaq Delisting Amid Appeal and 1-for-15 Reverse Stock SplitAs previously reported, on April 10, 2025, Nasdaq notified SCWorx Corp. (the Company) that based upon the Company's closing bid price for the previous 30 consecutive business days (February 26, 2025 through April 9, 2025), the Company no longer met the listed securities requirement to maintain a minimum bid price of $1 per share pursuant to Nasdaq Rules 5550(a)(2). On October 8, 2025, the Company received written notification from the Listing Qualifications Department of Nasdaq, granting the Company's request for a 180-day extension to regain compliance with the Bid Price Rule. The Company had until April 6, 2026 to meet the requirement. On April 7, 2026, Nasdaq notified the Company that, because it failed to regain compliance with Nasdaq's minimum bid price requirement of $1 per share pursuant to Nasdaq Rule 5550(a)(2), its securities will be delisted from the Capital Market. Consequently, trading of the Company's common stock will be suspended at the opening of business on April 14, 2026, and a Form 25-NSE will be filed with the Securities and Exchange Commission (the SEC), which will remove the Company's securities from listing and registration on The Nasdaq Stock Market. The Company has filed an appeal of the Nasdaq Staff's delisting determination to a hearings panel pursuant to the procedures set in the applicable Nasdaq Listing Rules. On April 7, 2026, the Company amended its certificate of incorporation to effect a 1 for 15 reverse stock split of its common stock, in order to regain compliance with Nasdaq's minimum bid price requirement of $1 per share. The effect of the reverse stock split is to combine every 15 shares of outstanding common stock into one share of common stock. The reverse stock split was effective at the opening of the trading day on April 10, 2026. In order for the Company to regain compliance with such Nasdaq rule, the Company's common stock must trade at or above $1.00 per share for ten consecutive trading days. Although the Company expects that it will regain compliance with Nasdaq's minimum bid price rule, as a result of the reverse stock split, there is no assurance that the Company will regain compliance or that it will be successful in its appeal of the delisting determination. If the Company is not successful in its appeal of the Nasdaq Staff's delisting determination, the Company's common stock will not resume trading on the Nasdaq Stock Market, which could have an adverse effect on the Company.Reported Earnings • Apr 04Full year 2025 earnings released: US$0.61 loss per share (vs US$0.78 loss in FY 2024)Full year 2025 results: US$0.61 loss per share. Revenue: US$2.88m (down 3.7% from FY 2024). Net loss: US$4.44m (loss widened 291% from FY 2024).Reported Earnings • Nov 14Third quarter 2025 earnings released: US$0.15 loss per share (vs US$0.27 loss in 3Q 2024)Third quarter 2025 results: US$0.15 loss per share. Revenue: US$705.8k (down 7.1% from 3Q 2024). Net loss: US$1.31m (loss widened 209% from 3Q 2024).お知らせ • Oct 15+ 1 more updateSCWorx Corp., Annual General Meeting, Dec 08, 2025SCWorx Corp., Annual General Meeting, Dec 08, 2025. Location: regus conference room at 35 village rd, suite 100 middleton, ma 01949, United Statesお知らせ • Sep 03SCWorx Corp. Appoints Anders Ohlsson as Chief Technology OfficerSCWorx Corp. announced the appointment of Anders Ohlsson, a seasoned technology executive, as its new Chief Technology Officer (CTO). This strategic hire underscores SCWorx’s commitment to advancing its data platform and expanding its suite of data management and software solutions for healthcare providers. Mr. Ohlsson has over 25 years of experience in software engineering, cloud infrastructure, and machine learning applications. Prior to joining SCWorx, he held senior leadership roles at WideOrbit, where he spearheaded the development of scalable SaaS platforms and led cross-functional teams in delivering enterprise-grade technology solutions. As CTO, Mr. Ohlsson will oversee the company’s technology strategy, product development roadmap, and innovation initiatives. The appointment comes at a pivotal time as SCWorx expands its capabilities in data management, data cleanse, system integration and analytics to meet the growing demands of healthcare organizations navigating complex operational challenges.最新情報をもっと見るRecent updatesお知らせ • Apr 15SCWorx Corp.(OTCPK:WORX) dropped from NASDAQ Composite IndexSCWorx Corp. has been dropped from the NASDAQ Composite Index .お知らせ • Apr 11SCWorx Corp. Faces Nasdaq Delisting Amid Appeal and 1-for-15 Reverse Stock SplitAs previously reported, on April 10, 2025, Nasdaq notified SCWorx Corp. (the Company) that based upon the Company's closing bid price for the previous 30 consecutive business days (February 26, 2025 through April 9, 2025), the Company no longer met the listed securities requirement to maintain a minimum bid price of $1 per share pursuant to Nasdaq Rules 5550(a)(2). On October 8, 2025, the Company received written notification from the Listing Qualifications Department of Nasdaq, granting the Company's request for a 180-day extension to regain compliance with the Bid Price Rule. The Company had until April 6, 2026 to meet the requirement. On April 7, 2026, Nasdaq notified the Company that, because it failed to regain compliance with Nasdaq's minimum bid price requirement of $1 per share pursuant to Nasdaq Rule 5550(a)(2), its securities will be delisted from the Capital Market. Consequently, trading of the Company's common stock will be suspended at the opening of business on April 14, 2026, and a Form 25-NSE will be filed with the Securities and Exchange Commission (the SEC), which will remove the Company's securities from listing and registration on The Nasdaq Stock Market. The Company has filed an appeal of the Nasdaq Staff's delisting determination to a hearings panel pursuant to the procedures set in the applicable Nasdaq Listing Rules. On April 7, 2026, the Company amended its certificate of incorporation to effect a 1 for 15 reverse stock split of its common stock, in order to regain compliance with Nasdaq's minimum bid price requirement of $1 per share. The effect of the reverse stock split is to combine every 15 shares of outstanding common stock into one share of common stock. The reverse stock split was effective at the opening of the trading day on April 10, 2026. In order for the Company to regain compliance with such Nasdaq rule, the Company's common stock must trade at or above $1.00 per share for ten consecutive trading days. Although the Company expects that it will regain compliance with Nasdaq's minimum bid price rule, as a result of the reverse stock split, there is no assurance that the Company will regain compliance or that it will be successful in its appeal of the delisting determination. If the Company is not successful in its appeal of the Nasdaq Staff's delisting determination, the Company's common stock will not resume trading on the Nasdaq Stock Market, which could have an adverse effect on the Company.Reported Earnings • Apr 04Full year 2025 earnings released: US$0.61 loss per share (vs US$0.78 loss in FY 2024)Full year 2025 results: US$0.61 loss per share. Revenue: US$2.88m (down 3.7% from FY 2024). Net loss: US$4.44m (loss widened 291% from FY 2024).Reported Earnings • Nov 14Third quarter 2025 earnings released: US$0.15 loss per share (vs US$0.27 loss in 3Q 2024)Third quarter 2025 results: US$0.15 loss per share. Revenue: US$705.8k (down 7.1% from 3Q 2024). Net loss: US$1.31m (loss widened 209% from 3Q 2024).お知らせ • Oct 15+ 1 more updateSCWorx Corp., Annual General Meeting, Dec 08, 2025SCWorx Corp., Annual General Meeting, Dec 08, 2025. Location: regus conference room at 35 village rd, suite 100 middleton, ma 01949, United Statesお知らせ • Sep 03SCWorx Corp. Appoints Anders Ohlsson as Chief Technology OfficerSCWorx Corp. announced the appointment of Anders Ohlsson, a seasoned technology executive, as its new Chief Technology Officer (CTO). This strategic hire underscores SCWorx’s commitment to advancing its data platform and expanding its suite of data management and software solutions for healthcare providers. Mr. Ohlsson has over 25 years of experience in software engineering, cloud infrastructure, and machine learning applications. Prior to joining SCWorx, he held senior leadership roles at WideOrbit, where he spearheaded the development of scalable SaaS platforms and led cross-functional teams in delivering enterprise-grade technology solutions. As CTO, Mr. Ohlsson will oversee the company’s technology strategy, product development roadmap, and innovation initiatives. The appointment comes at a pivotal time as SCWorx expands its capabilities in data management, data cleanse, system integration and analytics to meet the growing demands of healthcare organizations navigating complex operational challenges.Reported Earnings • Aug 15Second quarter 2025 earnings released: US$0.46 loss per share (vs US$0.26 loss in 2Q 2024)Second quarter 2025 results: US$0.46 loss per share (further deteriorated from US$0.26 loss in 2Q 2024). Revenue: US$682.6k (down 8.0% from 2Q 2024). Net loss: US$1.91m (loss widened 465% from 2Q 2024).お知らせ • Jan 23SCWorx Corp. announced that it has received $1.5 million in funding from Iroquois Capital Group, Inc., Iroquois Capital Management, LLC, Armas Capital Management, LLCSC Worx Corp. entered into a Securities Purchase Agreement with certain accredited investors on January 21, 2025. The company has issued senior secured convertible notes with an aggregate original principal amount of $1,500,000 and an initial conversion price of $1.25 per share, subject to adjustment as described in the Convertible Notes, and Series A warrants, Series B warrants and Series C warrants to acquire up to an aggregate amount of 7,200,000 additional shares of the Company’s common stock. The Warrants are exercisable immediately, one-third of which (the Series A Warrants) are exercisable at a price of $1.25 per share and two-thirds of which (the Series B Warrants and the Series C Warrants) are exercisable at a price of $1.375 per share, all expiring five years from the date of issuance. The Convertible Notes will accrue compounding interest at the rate of 10.0% per annum and will mature on January 21, 2027.お知らせ • Dec 03SCWorx Corp., Annual General Meeting, Dec 23, 2024SCWorx Corp., Annual General Meeting, Dec 23, 2024. Location: 35village rd, suite 100, middleton, massachusetts United Statesお知らせ • Nov 21+ 1 more updateSCWorx Announces Compliance with Nasdaq’s Periodic Reporting Listing StandardSCWorx Corp. announced that it has regained compliance with The Nasdaq Stock Market’s (“Nasdaq”) continued listing requirements regarding periodic reporting. On April 17, May 17, and August 19, 2024, Nasdaq notified the Company that it no longer met the Nasdaq’s periodic filing requirement under Listing Rule 5250(c)(1) (the “Rule”). In a letter dated October 14, 2024, Nasdaq indicated that based on the September 24, October 10, and October 11, 2024, filing of the Company’s Form 10-K for the year ended December 31, 2023, and Forms 10-Q for the periods ended March 31, and June 30, 2024, respectively, Staff had determined that the Company complies with the Rule and that the matter was now closed. At this time, all deficiencies of which the Company has been notified have been rectified, and Nasdaq considers these matters closed. As such, the Company’s common stock continues to be listed and trading on Nasdaq under the symbol “WORX”.お知らせ • Aug 25SCWorx Receives Notice of Non-Compliance from NASDAQ Stock Market Pertaining to its 10-Q for the quarter ended June 30, 2024On August 19, 2024, the Nasdaq Stock Market notified SCWorx Corp. that it has failed to satisfy a standard for continued listing, namely Nasdaq Listing Rule 5250(c)(1) (the “Rule), because the Company did not file its June 30, 2024 Quarterly Report on Form 10-Q by the due date of August 14, 2024 and because it remains delinquent in filing its Form 10-K for the period ended December 31, 2023 and its Form 10Q for the quarter ended March 31, 2024. As previously disclosed, due to the SEC’s Order denying BF Borgers CPA PC (“BF Borgers”) the privilege of appearing or practicing before the Commission as an accountant, on May 7, 2024, the board of directors of the Company dismissed BF Borgers CPA PC as the Company’s independent registered public accounting firm, at which time work on the Registrant’s periodic reports was delayed. As previously announced, the Company has engaged a new auditor, Astra Audit & Advisory, LLC to complete the audit and review of its annual and quarterly financial statements, respectively. The Company intends to complete the audit and review of its financial statements and file its 10K and 10Qs as quickly as possible to regain compliance with its periodic reporting obligations. The Company submitted Nasdaq a revised plan to regain compliance with the Rule by no later than October 14, 2024. The Nasdaq Staff has accepted the Company’s plan, granting the Company an extension of time until October 14, 2024 to regain compliance with the Rule’s periodic reporting obligations. The Company fully expects to file all its delinquent reports on or before this extended compliance date.お知らせ • Jul 17SCWorx Corp. announced that it has received $1.155 million in funding from Iroquois Capital Group, Inc., Iroquois Capital Management, LLC, Armas Capital Management LLCOn July 16, 2024, SCWorx Corp closed the transaction.お知らせ • May 22SCWorx Corp. Receives Non-Compliance Notice from NasdaqOn May 15, 2024, the Nasdaq Stock Market notified SCWorx Corp. that it has failed to satisfy a standard for continued listing, namely Nasdaq Listing Rule 5250(c)(1), because the company did not file its Quarterly Report on Form 10-Q by the due date of May 15, 2024 and because it remains delinquent in filing its Form 10-K for the period ended December 31, 2023. As previously disclosed, due to the SEC’s Order denying BF Borgers CPA PC (“BF Borgers”) the privilege of appearing or practicing before the Commission as an accountant, on May 7, 2024, the board of directors of the Company dismissed BF Borgers CPA PC as the company’s independent registered public accounting firm, at which time work on the company’s periodic reports was delayed. The company has engaged a new independent registered public accounting firm to complete the audit and review of its annual and quarterly financial statements, respectively, as expeditiously as possible, following which the company will promptly file its Annual Report on Form 10-K and Quarterly Report on Form 10-Q. The company intends to notify the Nasdaq of this plan to rectify the existing filing deficiencies.お知らせ • Apr 02SCWorx Corp. announced delayed annual 10-K filingOn 04/01/2024, SCWorx Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Aug 23SCWorx Corp. Announces Executive ChangesSCWorx Corp. appointed Vincent M. Matozzo, an individual, as an independent member of the Board of Directors, effective immediately, as a result of Mr. Matozzo’s having successfully passed a background check. Mr. Matozzo was named chair of the Nominating and Corporate Governance Committee, and a member of the Compensation Committee and Audit Committee of the Board of Directors. There are no family relationships between any director or executive officer of the Company and Mr. Matozzo. Mr. Matozzo is an innovative strategist and leader recognized for driving results through effective supply chain strategies and product innovation. He is a dynamic leader who drives change and delivers results for clients, corporations, and consortiums. He is passionate about automating processes and delivering a superior customer experience while enabling teams. Mr. Matozzo is a subject matter expert in Lean and Agile process modeling, with experience in all aspects of pre-award modeling to post-award monitoring, requisitioning to reimbursement- including data visualization and procurement. He has expertise in technical execution and supply chain innovation and enjoys deploying initiatives in technology development to continuously improve interoperability and operations. Mr. Matozzo is a featured speaker and expert in supply chain organizational development and business continuity. He is skilled in designing and implementing innovative business models that produce dramatic results. Mr. Matozzo has served in various supply chain capacities across manufacturing, aerospace, and healthcare at organizations including Yale New Haven Health, Vizient, and NYU Langone Health. On August 18, 2023, the board of directors of SCWorx Corp. received the resignation of John Ferrara, as an independent, outside director of the Company. Mr. Ferrara resigned for personal reasons. Mr. Ferrara did not advise the Company of any disagreement with the Company on any matter relating to its operations, policies or practices. The Board of Directors accepted Mr. Ferrara’s resignation with immediate effect.お知らせ • Aug 19SCWorx Corp., Annual General Meeting, Oct 06, 2023SCWorx Corp., Annual General Meeting, Oct 06, 2023. Location: Regus conference room, 35 Village Rd, Suite 100 Middleton, MA 01949 Middleton Massachusetts United States Agenda: To elect three directors to serve until the next annual meeting of stockholders and until their respective successors shall have been duly elected and qualified; to consider and act upon a proposed amendment of the Company’s certificate of incorporation to effect a TBD reverse stock split of the Company’s common stock; to consider and vote, on a non-binding, advisory basis, upon the compensation of those of executive officers listed in the Summary Compensation Table appearing elsewhere in this proxy statement, or named executive officers, as disclosed in this proxy statement pursuant to Item 402 of Regulation S-K; to ratify the selection of BF Borgers CPA PC as independent registered public accounting firm of the Company for the fiscal year ending December 31, 2023; and to consider and act upon such other business as may properly come before the meeting or any adjournment or postponement thereof.お知らせ • Jun 10SCWorx Announces Notice of Delisting or Failure to Satisfy A Continued Listing Rule or StandardAs previously disclosed, on June 9, 2022, the Listing Qualifications department of The Nasdaq Stock Market LLC notified SCWorx Corp. that the bid price of its common stock had closed at less than $1 per share over the previous 30 consecutive business days, and, as a result, did not comply with Listing Rule 5550(a)(2). In accordance with Listing Rule 5810(c)(3)(A), the Company was provided 180 calendar days, or until December 5, 2022, to regain compliance with the Rule. On December 6, 2022, the Company received a determination letter from the Staff advising the Company that the Staff had determined that the Company had not regained compliance with the Rule and that the Company was eligible for an additional 180 day period, or until June 5, 2023, to regain compliance with the Rule. On June 6, 2023, the Company received a determination letter from the Staff stating that the Company has not regained compliance with Listing Rule 5550(a)(2). Accordingly, its securities will be delisted from the Capital Market. In that regard, unless the Company requests an appeal of this determination then trading of the Company's common stock will be suspended at the opening of business on June 15, 2023, and a Form 25-NSE will be filed with the Securities and Exchange Commission (the SEC"), which will remove the Company's securities from listing and registration on The Nasdaq Stock Market. The Company may appeal Staff's determination to a Hearings Panel (the Panel"), pursuant to the procedures set in the Nasdaq Listing Rule 5800 Series. A hearing request will stay the suspension of the Company's securities and the filing of the Form 25-NSE pending the Panel's decision. The Company currently intends to appeal Nasdaq's determination to a hearings panel (the Panel"), pursuant to the procedures set in the Nasdaq Listing Rule 5800 Series and, as disclosed in prior 8-K on June 13, 2022, take any steps necessary to effect a reverse stock split as necessary. Hearings are typically scheduled to occur approximately 30-45 days after the date of the hearing request. At the Panel hearing, the Company intends to present a plan to regain compliance with the Rule. There can be no assurance that the Company's plan will be accepted by the Panel or that, if it is, the Company will be able to regain compliance with the applicable Nasdaq listing requirements, or that a Panel will stay the suspension of the Company's securities. If the Company's securities are delisted from Nasdaq, it could be more difficult to buy or sell the Company's common stock and warrants or to obtain accurate quotations, and the price of the Company's common stock and warrants could suffer a material decline. Delisting could also impair the Company's ability to raise capital and/or trigger defaults and penalties under outstanding agreements or securities of the Company.Seeking Alpha • Aug 30SCWorx renews, expands data service agreement with 500+ bed hospital in New EnglandSCWorx (NASDAQ:WORX) on Tuesday said it had renewed and expanded a data service agreement with an existing 500+ bed hospital in New England. WORX and the hospital had previously entered into a 1 year, $125K agreement. The new agreement is for 4 years at $200K per year. WORX did not name or identify the hospital. WORX said the new agreement included currently provided services as well as extended services. WORX stock +1.6% to $0.66 in afternoon trading.Seeking Alpha • Jul 05SCWorx climbs 10% on $5M stock buyback agreementSCWorx (NASDAQ:WORX) entered stock purchase agreement with an institutional investor. Company will have the right, but not the obligation, to issue and sell to the investor up to $5M of common stock from time-to-time over the ~24-month term of the purchase agreement. Tim Hannibal, President & CEO commented, “We believe this commitment from the Institutional Investor demonstrates investor confidence in SCWorx, including our business model that leverages the SCWorx data management SaaS solution to assist hospitals in achieving their supply chain goals and cost savings objectives.” Company currently has a market cap of $7.9M.Reported Earnings • Apr 02Full year 2021 earnings released: US$0.36 loss per share (vs US$0.82 loss in FY 2020)Full year 2021 results: US$0.36 loss per share (up from US$0.82 loss in FY 2020). Revenue: US$4.63m (down 11% from FY 2020). Net loss: US$3.81m (loss narrowed 49% from FY 2020). Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings.Reported Earnings • Nov 17Third quarter 2021 earnings released: US$0.09 loss per share (vs US$0.42 loss in 3Q 2020)The company reported a decent third quarter result with reduced losses and improved control over expenses, although revenues were weaker. Third quarter 2021 results: Revenue: US$1.14m (down 2.8% from 3Q 2020). Net loss: US$961.8k (loss narrowed 77% from 3Q 2020).Board Change • Sep 02High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Independent Director Steven Wallitt is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Recent Insider Transactions • Aug 22Independent Director recently sold US$315k worth of stockOn the 19th of August, Steven Wallitt sold around 100k shares on-market at roughly US$3.15 per share. In the last 3 months, there was an even bigger sale from another insider worth US$365k. Insiders have been net sellers, collectively disposing of US$1.1m more than they bought in the last 12 months.Recent Insider Transactions • Aug 18Insider recently sold US$210k worth of stockOn the 9th of August, Marc Schessel sold around 50k shares on-market at roughly US$4.20 per share. In the last 3 months, they made an even bigger sale worth US$365k. Insiders have been net sellers, collectively disposing of US$753k more than they bought in the last 12 months.Reported Earnings • Aug 18Second quarter 2021 earnings released: US$0.12 loss per share (vs US$0.41 loss in 2Q 2020)The company reported a decent second quarter result with reduced losses and improved control over expenses, although revenues were weaker. Second quarter 2021 results: Revenue: US$1.10m (down 24% from 2Q 2020). Net loss: US$1.25m (loss narrowed 67% from 2Q 2020).Is New 90 Day High Low • Feb 03New 90-day high: US$2.26The company is up 119% from its price of US$1.03 on 04 November 2020. The American market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is up 22% over the same period.Is New 90 Day High Low • Nov 28New 90-day high: US$2.22The company is up 7.0% from its price of US$2.07 on 28 August 2020. The American market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is up 5.0% over the same period.Reported Earnings • Nov 18Third quarter 2020 earnings released: US$0.42 loss per shareThe company reported a poor third quarter result with increased losses and weaker revenues and control over expenses. Third quarter 2020 results: Revenue: US$1.17m (down 30% from 3Q 2019). Net loss: US$4.09m (loss widened US$3.45m from 3Q 2019).お知らせ • Jul 02SCWorx Corp.(NasdaqCM:WORX) dropped from Russell Microcap IndexSCWorx Corp.(NasdaqCM:WORX) dropped from Russell Microcap Indexお知らせ • Jun 30SCWorx Corp. announced delayed 10-Q filingOn 06/29/2020, SCWorx Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Jun 17SCWorx Corp. Auditor Raises 'Going Concern' DoubtSCWorx Corp. filed its 10-K on Jun 12, 2020 for the period ending Dec 31, 2019. In this report its auditor, WithumSmith+Brown, PC , gave an unqualified opinion expressing doubt that the company can continue as a going concern.株主還元WORXUS Healthcare ServicesUS 市場7D2.8%2.7%1.1%1Y-93.9%-38.3%28.7%株主還元を見る業界別リターン: WORX過去 1 年間で-38.3 % の収益を上げたUS Healthcare Services業界を下回りました。リターン対市場: WORXは、過去 1 年間で28.7 % のリターンを上げたUS市場を下回りました。価格変動Is WORX's price volatile compared to industry and market?WORX volatilityWORX Average Weekly Movement32.1%Healthcare Services Industry Average Movement10.4%Market Average Movement7.2%10% most volatile stocks in US Market16.5%10% least volatile stocks in US Market3.1%安定した株価: WORXの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: WORXの 週次ボラティリティ は、過去 1 年間で23%から32%に増加しました。会社概要設立従業員CEO（最高経営責任者ウェブサイトn/a9Tim Hannibalwww.scworx.comSCWorx Corp.は、その子会社とともに、米国の医療提供者向けに情報の修復、正規化、相互運用性に関するデータコンテンツとサービスを提供している。同社は、病院やその他の医療施設内の医療プロセスや情報の流れを改善する医療情報技術ソリューションと関連サービスを開発・販売している。同社のソフトウェアモジュールは、仮想化された品目マスターファイルの修復、拡張、自動化、電子カルテ管理、料金明細マスター管理、契約管理、提案依頼の自動化、買収した事業の統合、リベート管理、ビッグデータ分析モデル、データ統合およびウェアハウスなどの個別の機能を実行する。同社は、直販部隊、流通および再販業者とのパートナーシップを通じて、病院や医療システムにソリューションとサービスを販売している。SCWorx Corp.はフロリダ州タンパを拠点としている。もっと見るSCWorx Corp. 基礎のまとめSCWorx の収益と売上を時価総額と比較するとどうか。WORX 基礎統計学時価総額US$394.76k収益（TTM）-US$4.14m売上高(TTM)US$2.90m0.1xP/Sレシオ-0.1xPER（株価収益率WORX は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計WORX 損益計算書（TTM）収益US$2.90m売上原価US$1.75m売上総利益US$1.16mその他の費用US$5.30m収益-US$4.14m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-3.88グロス・マージン39.86%純利益率-142.70%有利子負債／自己資本比率2.1%WORX の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/24 12:36終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋SCWorx Corp. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Apr 15SCWorx Corp.(OTCPK:WORX) dropped from NASDAQ Composite IndexSCWorx Corp. has been dropped from the NASDAQ Composite Index .
お知らせ • Apr 11SCWorx Corp. Faces Nasdaq Delisting Amid Appeal and 1-for-15 Reverse Stock SplitAs previously reported, on April 10, 2025, Nasdaq notified SCWorx Corp. (the Company) that based upon the Company's closing bid price for the previous 30 consecutive business days (February 26, 2025 through April 9, 2025), the Company no longer met the listed securities requirement to maintain a minimum bid price of $1 per share pursuant to Nasdaq Rules 5550(a)(2). On October 8, 2025, the Company received written notification from the Listing Qualifications Department of Nasdaq, granting the Company's request for a 180-day extension to regain compliance with the Bid Price Rule. The Company had until April 6, 2026 to meet the requirement. On April 7, 2026, Nasdaq notified the Company that, because it failed to regain compliance with Nasdaq's minimum bid price requirement of $1 per share pursuant to Nasdaq Rule 5550(a)(2), its securities will be delisted from the Capital Market. Consequently, trading of the Company's common stock will be suspended at the opening of business on April 14, 2026, and a Form 25-NSE will be filed with the Securities and Exchange Commission (the SEC), which will remove the Company's securities from listing and registration on The Nasdaq Stock Market. The Company has filed an appeal of the Nasdaq Staff's delisting determination to a hearings panel pursuant to the procedures set in the applicable Nasdaq Listing Rules. On April 7, 2026, the Company amended its certificate of incorporation to effect a 1 for 15 reverse stock split of its common stock, in order to regain compliance with Nasdaq's minimum bid price requirement of $1 per share. The effect of the reverse stock split is to combine every 15 shares of outstanding common stock into one share of common stock. The reverse stock split was effective at the opening of the trading day on April 10, 2026. In order for the Company to regain compliance with such Nasdaq rule, the Company's common stock must trade at or above $1.00 per share for ten consecutive trading days. Although the Company expects that it will regain compliance with Nasdaq's minimum bid price rule, as a result of the reverse stock split, there is no assurance that the Company will regain compliance or that it will be successful in its appeal of the delisting determination. If the Company is not successful in its appeal of the Nasdaq Staff's delisting determination, the Company's common stock will not resume trading on the Nasdaq Stock Market, which could have an adverse effect on the Company.
Reported Earnings • Apr 04Full year 2025 earnings released: US$0.61 loss per share (vs US$0.78 loss in FY 2024)Full year 2025 results: US$0.61 loss per share. Revenue: US$2.88m (down 3.7% from FY 2024). Net loss: US$4.44m (loss widened 291% from FY 2024).
Reported Earnings • Nov 14Third quarter 2025 earnings released: US$0.15 loss per share (vs US$0.27 loss in 3Q 2024)Third quarter 2025 results: US$0.15 loss per share. Revenue: US$705.8k (down 7.1% from 3Q 2024). Net loss: US$1.31m (loss widened 209% from 3Q 2024).
お知らせ • Oct 15+ 1 more updateSCWorx Corp., Annual General Meeting, Dec 08, 2025SCWorx Corp., Annual General Meeting, Dec 08, 2025. Location: regus conference room at 35 village rd, suite 100 middleton, ma 01949, United States
お知らせ • Sep 03SCWorx Corp. Appoints Anders Ohlsson as Chief Technology OfficerSCWorx Corp. announced the appointment of Anders Ohlsson, a seasoned technology executive, as its new Chief Technology Officer (CTO). This strategic hire underscores SCWorx’s commitment to advancing its data platform and expanding its suite of data management and software solutions for healthcare providers. Mr. Ohlsson has over 25 years of experience in software engineering, cloud infrastructure, and machine learning applications. Prior to joining SCWorx, he held senior leadership roles at WideOrbit, where he spearheaded the development of scalable SaaS platforms and led cross-functional teams in delivering enterprise-grade technology solutions. As CTO, Mr. Ohlsson will oversee the company’s technology strategy, product development roadmap, and innovation initiatives. The appointment comes at a pivotal time as SCWorx expands its capabilities in data management, data cleanse, system integration and analytics to meet the growing demands of healthcare organizations navigating complex operational challenges.
お知らせ • Apr 15SCWorx Corp.(OTCPK:WORX) dropped from NASDAQ Composite IndexSCWorx Corp. has been dropped from the NASDAQ Composite Index .
お知らせ • Apr 11SCWorx Corp. Faces Nasdaq Delisting Amid Appeal and 1-for-15 Reverse Stock SplitAs previously reported, on April 10, 2025, Nasdaq notified SCWorx Corp. (the Company) that based upon the Company's closing bid price for the previous 30 consecutive business days (February 26, 2025 through April 9, 2025), the Company no longer met the listed securities requirement to maintain a minimum bid price of $1 per share pursuant to Nasdaq Rules 5550(a)(2). On October 8, 2025, the Company received written notification from the Listing Qualifications Department of Nasdaq, granting the Company's request for a 180-day extension to regain compliance with the Bid Price Rule. The Company had until April 6, 2026 to meet the requirement. On April 7, 2026, Nasdaq notified the Company that, because it failed to regain compliance with Nasdaq's minimum bid price requirement of $1 per share pursuant to Nasdaq Rule 5550(a)(2), its securities will be delisted from the Capital Market. Consequently, trading of the Company's common stock will be suspended at the opening of business on April 14, 2026, and a Form 25-NSE will be filed with the Securities and Exchange Commission (the SEC), which will remove the Company's securities from listing and registration on The Nasdaq Stock Market. The Company has filed an appeal of the Nasdaq Staff's delisting determination to a hearings panel pursuant to the procedures set in the applicable Nasdaq Listing Rules. On April 7, 2026, the Company amended its certificate of incorporation to effect a 1 for 15 reverse stock split of its common stock, in order to regain compliance with Nasdaq's minimum bid price requirement of $1 per share. The effect of the reverse stock split is to combine every 15 shares of outstanding common stock into one share of common stock. The reverse stock split was effective at the opening of the trading day on April 10, 2026. In order for the Company to regain compliance with such Nasdaq rule, the Company's common stock must trade at or above $1.00 per share for ten consecutive trading days. Although the Company expects that it will regain compliance with Nasdaq's minimum bid price rule, as a result of the reverse stock split, there is no assurance that the Company will regain compliance or that it will be successful in its appeal of the delisting determination. If the Company is not successful in its appeal of the Nasdaq Staff's delisting determination, the Company's common stock will not resume trading on the Nasdaq Stock Market, which could have an adverse effect on the Company.
Reported Earnings • Apr 04Full year 2025 earnings released: US$0.61 loss per share (vs US$0.78 loss in FY 2024)Full year 2025 results: US$0.61 loss per share. Revenue: US$2.88m (down 3.7% from FY 2024). Net loss: US$4.44m (loss widened 291% from FY 2024).
Reported Earnings • Nov 14Third quarter 2025 earnings released: US$0.15 loss per share (vs US$0.27 loss in 3Q 2024)Third quarter 2025 results: US$0.15 loss per share. Revenue: US$705.8k (down 7.1% from 3Q 2024). Net loss: US$1.31m (loss widened 209% from 3Q 2024).
お知らせ • Oct 15+ 1 more updateSCWorx Corp., Annual General Meeting, Dec 08, 2025SCWorx Corp., Annual General Meeting, Dec 08, 2025. Location: regus conference room at 35 village rd, suite 100 middleton, ma 01949, United States
お知らせ • Sep 03SCWorx Corp. Appoints Anders Ohlsson as Chief Technology OfficerSCWorx Corp. announced the appointment of Anders Ohlsson, a seasoned technology executive, as its new Chief Technology Officer (CTO). This strategic hire underscores SCWorx’s commitment to advancing its data platform and expanding its suite of data management and software solutions for healthcare providers. Mr. Ohlsson has over 25 years of experience in software engineering, cloud infrastructure, and machine learning applications. Prior to joining SCWorx, he held senior leadership roles at WideOrbit, where he spearheaded the development of scalable SaaS platforms and led cross-functional teams in delivering enterprise-grade technology solutions. As CTO, Mr. Ohlsson will oversee the company’s technology strategy, product development roadmap, and innovation initiatives. The appointment comes at a pivotal time as SCWorx expands its capabilities in data management, data cleanse, system integration and analytics to meet the growing demands of healthcare organizations navigating complex operational challenges.
Reported Earnings • Aug 15Second quarter 2025 earnings released: US$0.46 loss per share (vs US$0.26 loss in 2Q 2024)Second quarter 2025 results: US$0.46 loss per share (further deteriorated from US$0.26 loss in 2Q 2024). Revenue: US$682.6k (down 8.0% from 2Q 2024). Net loss: US$1.91m (loss widened 465% from 2Q 2024).
お知らせ • Jan 23SCWorx Corp. announced that it has received $1.5 million in funding from Iroquois Capital Group, Inc., Iroquois Capital Management, LLC, Armas Capital Management, LLCSC Worx Corp. entered into a Securities Purchase Agreement with certain accredited investors on January 21, 2025. The company has issued senior secured convertible notes with an aggregate original principal amount of $1,500,000 and an initial conversion price of $1.25 per share, subject to adjustment as described in the Convertible Notes, and Series A warrants, Series B warrants and Series C warrants to acquire up to an aggregate amount of 7,200,000 additional shares of the Company’s common stock. The Warrants are exercisable immediately, one-third of which (the Series A Warrants) are exercisable at a price of $1.25 per share and two-thirds of which (the Series B Warrants and the Series C Warrants) are exercisable at a price of $1.375 per share, all expiring five years from the date of issuance. The Convertible Notes will accrue compounding interest at the rate of 10.0% per annum and will mature on January 21, 2027.
お知らせ • Dec 03SCWorx Corp., Annual General Meeting, Dec 23, 2024SCWorx Corp., Annual General Meeting, Dec 23, 2024. Location: 35village rd, suite 100, middleton, massachusetts United States
お知らせ • Nov 21+ 1 more updateSCWorx Announces Compliance with Nasdaq’s Periodic Reporting Listing StandardSCWorx Corp. announced that it has regained compliance with The Nasdaq Stock Market’s (“Nasdaq”) continued listing requirements regarding periodic reporting. On April 17, May 17, and August 19, 2024, Nasdaq notified the Company that it no longer met the Nasdaq’s periodic filing requirement under Listing Rule 5250(c)(1) (the “Rule”). In a letter dated October 14, 2024, Nasdaq indicated that based on the September 24, October 10, and October 11, 2024, filing of the Company’s Form 10-K for the year ended December 31, 2023, and Forms 10-Q for the periods ended March 31, and June 30, 2024, respectively, Staff had determined that the Company complies with the Rule and that the matter was now closed. At this time, all deficiencies of which the Company has been notified have been rectified, and Nasdaq considers these matters closed. As such, the Company’s common stock continues to be listed and trading on Nasdaq under the symbol “WORX”.
お知らせ • Aug 25SCWorx Receives Notice of Non-Compliance from NASDAQ Stock Market Pertaining to its 10-Q for the quarter ended June 30, 2024On August 19, 2024, the Nasdaq Stock Market notified SCWorx Corp. that it has failed to satisfy a standard for continued listing, namely Nasdaq Listing Rule 5250(c)(1) (the “Rule), because the Company did not file its June 30, 2024 Quarterly Report on Form 10-Q by the due date of August 14, 2024 and because it remains delinquent in filing its Form 10-K for the period ended December 31, 2023 and its Form 10Q for the quarter ended March 31, 2024. As previously disclosed, due to the SEC’s Order denying BF Borgers CPA PC (“BF Borgers”) the privilege of appearing or practicing before the Commission as an accountant, on May 7, 2024, the board of directors of the Company dismissed BF Borgers CPA PC as the Company’s independent registered public accounting firm, at which time work on the Registrant’s periodic reports was delayed. As previously announced, the Company has engaged a new auditor, Astra Audit & Advisory, LLC to complete the audit and review of its annual and quarterly financial statements, respectively. The Company intends to complete the audit and review of its financial statements and file its 10K and 10Qs as quickly as possible to regain compliance with its periodic reporting obligations. The Company submitted Nasdaq a revised plan to regain compliance with the Rule by no later than October 14, 2024. The Nasdaq Staff has accepted the Company’s plan, granting the Company an extension of time until October 14, 2024 to regain compliance with the Rule’s periodic reporting obligations. The Company fully expects to file all its delinquent reports on or before this extended compliance date.
お知らせ • Jul 17SCWorx Corp. announced that it has received $1.155 million in funding from Iroquois Capital Group, Inc., Iroquois Capital Management, LLC, Armas Capital Management LLCOn July 16, 2024, SCWorx Corp closed the transaction.
お知らせ • May 22SCWorx Corp. Receives Non-Compliance Notice from NasdaqOn May 15, 2024, the Nasdaq Stock Market notified SCWorx Corp. that it has failed to satisfy a standard for continued listing, namely Nasdaq Listing Rule 5250(c)(1), because the company did not file its Quarterly Report on Form 10-Q by the due date of May 15, 2024 and because it remains delinquent in filing its Form 10-K for the period ended December 31, 2023. As previously disclosed, due to the SEC’s Order denying BF Borgers CPA PC (“BF Borgers”) the privilege of appearing or practicing before the Commission as an accountant, on May 7, 2024, the board of directors of the Company dismissed BF Borgers CPA PC as the company’s independent registered public accounting firm, at which time work on the company’s periodic reports was delayed. The company has engaged a new independent registered public accounting firm to complete the audit and review of its annual and quarterly financial statements, respectively, as expeditiously as possible, following which the company will promptly file its Annual Report on Form 10-K and Quarterly Report on Form 10-Q. The company intends to notify the Nasdaq of this plan to rectify the existing filing deficiencies.
お知らせ • Apr 02SCWorx Corp. announced delayed annual 10-K filingOn 04/01/2024, SCWorx Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Aug 23SCWorx Corp. Announces Executive ChangesSCWorx Corp. appointed Vincent M. Matozzo, an individual, as an independent member of the Board of Directors, effective immediately, as a result of Mr. Matozzo’s having successfully passed a background check. Mr. Matozzo was named chair of the Nominating and Corporate Governance Committee, and a member of the Compensation Committee and Audit Committee of the Board of Directors. There are no family relationships between any director or executive officer of the Company and Mr. Matozzo. Mr. Matozzo is an innovative strategist and leader recognized for driving results through effective supply chain strategies and product innovation. He is a dynamic leader who drives change and delivers results for clients, corporations, and consortiums. He is passionate about automating processes and delivering a superior customer experience while enabling teams. Mr. Matozzo is a subject matter expert in Lean and Agile process modeling, with experience in all aspects of pre-award modeling to post-award monitoring, requisitioning to reimbursement- including data visualization and procurement. He has expertise in technical execution and supply chain innovation and enjoys deploying initiatives in technology development to continuously improve interoperability and operations. Mr. Matozzo is a featured speaker and expert in supply chain organizational development and business continuity. He is skilled in designing and implementing innovative business models that produce dramatic results. Mr. Matozzo has served in various supply chain capacities across manufacturing, aerospace, and healthcare at organizations including Yale New Haven Health, Vizient, and NYU Langone Health. On August 18, 2023, the board of directors of SCWorx Corp. received the resignation of John Ferrara, as an independent, outside director of the Company. Mr. Ferrara resigned for personal reasons. Mr. Ferrara did not advise the Company of any disagreement with the Company on any matter relating to its operations, policies or practices. The Board of Directors accepted Mr. Ferrara’s resignation with immediate effect.
お知らせ • Aug 19SCWorx Corp., Annual General Meeting, Oct 06, 2023SCWorx Corp., Annual General Meeting, Oct 06, 2023. Location: Regus conference room, 35 Village Rd, Suite 100 Middleton, MA 01949 Middleton Massachusetts United States Agenda: To elect three directors to serve until the next annual meeting of stockholders and until their respective successors shall have been duly elected and qualified; to consider and act upon a proposed amendment of the Company’s certificate of incorporation to effect a TBD reverse stock split of the Company’s common stock; to consider and vote, on a non-binding, advisory basis, upon the compensation of those of executive officers listed in the Summary Compensation Table appearing elsewhere in this proxy statement, or named executive officers, as disclosed in this proxy statement pursuant to Item 402 of Regulation S-K; to ratify the selection of BF Borgers CPA PC as independent registered public accounting firm of the Company for the fiscal year ending December 31, 2023; and to consider and act upon such other business as may properly come before the meeting or any adjournment or postponement thereof.
お知らせ • Jun 10SCWorx Announces Notice of Delisting or Failure to Satisfy A Continued Listing Rule or StandardAs previously disclosed, on June 9, 2022, the Listing Qualifications department of The Nasdaq Stock Market LLC notified SCWorx Corp. that the bid price of its common stock had closed at less than $1 per share over the previous 30 consecutive business days, and, as a result, did not comply with Listing Rule 5550(a)(2). In accordance with Listing Rule 5810(c)(3)(A), the Company was provided 180 calendar days, or until December 5, 2022, to regain compliance with the Rule. On December 6, 2022, the Company received a determination letter from the Staff advising the Company that the Staff had determined that the Company had not regained compliance with the Rule and that the Company was eligible for an additional 180 day period, or until June 5, 2023, to regain compliance with the Rule. On June 6, 2023, the Company received a determination letter from the Staff stating that the Company has not regained compliance with Listing Rule 5550(a)(2). Accordingly, its securities will be delisted from the Capital Market. In that regard, unless the Company requests an appeal of this determination then trading of the Company's common stock will be suspended at the opening of business on June 15, 2023, and a Form 25-NSE will be filed with the Securities and Exchange Commission (the SEC"), which will remove the Company's securities from listing and registration on The Nasdaq Stock Market. The Company may appeal Staff's determination to a Hearings Panel (the Panel"), pursuant to the procedures set in the Nasdaq Listing Rule 5800 Series. A hearing request will stay the suspension of the Company's securities and the filing of the Form 25-NSE pending the Panel's decision. The Company currently intends to appeal Nasdaq's determination to a hearings panel (the Panel"), pursuant to the procedures set in the Nasdaq Listing Rule 5800 Series and, as disclosed in prior 8-K on June 13, 2022, take any steps necessary to effect a reverse stock split as necessary. Hearings are typically scheduled to occur approximately 30-45 days after the date of the hearing request. At the Panel hearing, the Company intends to present a plan to regain compliance with the Rule. There can be no assurance that the Company's plan will be accepted by the Panel or that, if it is, the Company will be able to regain compliance with the applicable Nasdaq listing requirements, or that a Panel will stay the suspension of the Company's securities. If the Company's securities are delisted from Nasdaq, it could be more difficult to buy or sell the Company's common stock and warrants or to obtain accurate quotations, and the price of the Company's common stock and warrants could suffer a material decline. Delisting could also impair the Company's ability to raise capital and/or trigger defaults and penalties under outstanding agreements or securities of the Company.
Seeking Alpha • Aug 30SCWorx renews, expands data service agreement with 500+ bed hospital in New EnglandSCWorx (NASDAQ:WORX) on Tuesday said it had renewed and expanded a data service agreement with an existing 500+ bed hospital in New England. WORX and the hospital had previously entered into a 1 year, $125K agreement. The new agreement is for 4 years at $200K per year. WORX did not name or identify the hospital. WORX said the new agreement included currently provided services as well as extended services. WORX stock +1.6% to $0.66 in afternoon trading.
Seeking Alpha • Jul 05SCWorx climbs 10% on $5M stock buyback agreementSCWorx (NASDAQ:WORX) entered stock purchase agreement with an institutional investor. Company will have the right, but not the obligation, to issue and sell to the investor up to $5M of common stock from time-to-time over the ~24-month term of the purchase agreement. Tim Hannibal, President & CEO commented, “We believe this commitment from the Institutional Investor demonstrates investor confidence in SCWorx, including our business model that leverages the SCWorx data management SaaS solution to assist hospitals in achieving their supply chain goals and cost savings objectives.” Company currently has a market cap of $7.9M.
Reported Earnings • Apr 02Full year 2021 earnings released: US$0.36 loss per share (vs US$0.82 loss in FY 2020)Full year 2021 results: US$0.36 loss per share (up from US$0.82 loss in FY 2020). Revenue: US$4.63m (down 11% from FY 2020). Net loss: US$3.81m (loss narrowed 49% from FY 2020). Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings.
Reported Earnings • Nov 17Third quarter 2021 earnings released: US$0.09 loss per share (vs US$0.42 loss in 3Q 2020)The company reported a decent third quarter result with reduced losses and improved control over expenses, although revenues were weaker. Third quarter 2021 results: Revenue: US$1.14m (down 2.8% from 3Q 2020). Net loss: US$961.8k (loss narrowed 77% from 3Q 2020).
Board Change • Sep 02High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Independent Director Steven Wallitt is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Recent Insider Transactions • Aug 22Independent Director recently sold US$315k worth of stockOn the 19th of August, Steven Wallitt sold around 100k shares on-market at roughly US$3.15 per share. In the last 3 months, there was an even bigger sale from another insider worth US$365k. Insiders have been net sellers, collectively disposing of US$1.1m more than they bought in the last 12 months.
Recent Insider Transactions • Aug 18Insider recently sold US$210k worth of stockOn the 9th of August, Marc Schessel sold around 50k shares on-market at roughly US$4.20 per share. In the last 3 months, they made an even bigger sale worth US$365k. Insiders have been net sellers, collectively disposing of US$753k more than they bought in the last 12 months.
Reported Earnings • Aug 18Second quarter 2021 earnings released: US$0.12 loss per share (vs US$0.41 loss in 2Q 2020)The company reported a decent second quarter result with reduced losses and improved control over expenses, although revenues were weaker. Second quarter 2021 results: Revenue: US$1.10m (down 24% from 2Q 2020). Net loss: US$1.25m (loss narrowed 67% from 2Q 2020).
Is New 90 Day High Low • Feb 03New 90-day high: US$2.26The company is up 119% from its price of US$1.03 on 04 November 2020. The American market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is up 22% over the same period.
Is New 90 Day High Low • Nov 28New 90-day high: US$2.22The company is up 7.0% from its price of US$2.07 on 28 August 2020. The American market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is up 5.0% over the same period.
Reported Earnings • Nov 18Third quarter 2020 earnings released: US$0.42 loss per shareThe company reported a poor third quarter result with increased losses and weaker revenues and control over expenses. Third quarter 2020 results: Revenue: US$1.17m (down 30% from 3Q 2019). Net loss: US$4.09m (loss widened US$3.45m from 3Q 2019).
お知らせ • Jul 02SCWorx Corp.(NasdaqCM:WORX) dropped from Russell Microcap IndexSCWorx Corp.(NasdaqCM:WORX) dropped from Russell Microcap Index
お知らせ • Jun 30SCWorx Corp. announced delayed 10-Q filingOn 06/29/2020, SCWorx Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Jun 17SCWorx Corp. Auditor Raises 'Going Concern' DoubtSCWorx Corp. filed its 10-K on Jun 12, 2020 for the period ending Dec 31, 2019. In this report its auditor, WithumSmith+Brown, PC , gave an unqualified opinion expressing doubt that the company can continue as a going concern.
